Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056537 · ClinicalTrials.gov registry record · Phase 1
ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer
A Phase 1 study, sponsored by Active Biotech AB.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT00056537 is a Phase 1 study that has completed, run by Active Biotech AB. The registered enrollment target is 44 participants.
The verdict
NCT00056537, a Phase 1 study, has completed, sponsored by Active Biotech AB.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The drug ABR-217620 is a combination of two proteins, one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the body's normal immune system. In animals, this results in an accumulation of white blood cells in the cancer that can fight the cancer. This study will test how much of the drug can be given to patients with non-small cell lung cancer, renal clear cell carcinoma, or pancreatic cancer without causing unacceptable side effects.
Interventions
- DRUG ABR-217620
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2003-04 |
| Est. Completion | 2006-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00056537
The ClinicalTrials.gov registry entry for NCT00056537 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Active Biotech AB, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABR-217620 is the first listed.
NCT00056537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00056537 about?
NCT00056537 is a clinical study titled "ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer". The drug ABR-217620 is a combination of two proteins, one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the body's normal immune system. In animals, this results in an accumulation of white blood cells in the cancer t...
What is the current status of trial NCT00056537?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2003-04. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00056537?
The interventions under investigation include: ABR-217620 (DRUG).
Who is sponsoring clinical trial NCT00056537?
This trial is sponsored by Active Biotech AB, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.